Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATG4B | Q9Y4P1 | 12/20 | 0.49 |
| ▸ | PLA2G1B | P04054 | 10/20 | 0.49 |
| ▸ | THRA | P10827 | 5/20 | 0.49 |
| ▸ | THRB | P10828 | 5/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RARB | P10826 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL499495 | 0.88 | THRA (0.43) | ATG4BPLA2G1BTHRATHRBCYP1A2 | |
| SCHEMBL3969868 | 0.88 | TP53 (0.46) | RARB | |
| SCHEMBL3974915 | 0.88 | TP53 (0.46) | RARB | |
| SCHEMBL3969907 | 0.88 | TP53 (0.46) | RARB | |
| SCHEMBL499220 | 0.88 | TP53 (0.46) | RARB | |
| SCHEMBL3968478 | 0.86 | PLK1 (0.40) | ATG4BPLA2G1BTHRATHRB | |
| SCHEMBL498698 | 0.85 | ATG4B (0.51) | ATG4BPLA2G1BTHRATHRBCYP1A2 | |
| SCHEMBL3969812 | 0.83 | CAPN1 (0.45) | TDP1 | |
| SCHEMBL3968303 | 0.83 | ABCG2 (0.47) | — | |
| SCHEMBL3972097 | 0.82 | LMNA (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129932-A1 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2012-05-24 | — | — | US | claimed |
| US-7943661-B2 | Antiischemic agents; for example 1-[2-hydroxy-4-chlorophenyl]-3-[4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one; display peroxisome proliferator activated receptor (PPAR) activator, antioxidant and antiinflammatory properties | GENFIT (FR) | 2011-05-17 | — | — | US | claimed |
| US-7566737-B2 | Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2009-07-28 | — | — | US | claimed |
| EP-1525177-B1 | SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2007-06-27 | — | — | EP | claimed |
| EP-1519908-B1 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2007-06-13 | — | — | EP | claimed |
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | GENFIT (FR) | 2007-02-08 | — | — | US | claimed |
| US-20050171149-A1 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2005-08-04 | — | — | US | claimed |
| EP-1525177-A1 | SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES AND PREPARATION AND USES THEREOF | Genfit (FR) | 2005-04-27 | — | — | EP | claimed |
| EP-1519908-A2 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | Genfit (FR) | 2005-04-06 | — | — | EP | claimed |
| WO-2004005243-A2 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES | GENFIT (FR) | 2004-01-15 | — | — | WO | claimed |
| WO-2004005233-A1 | SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES AND PREPARATION AND USES THEREOF | GENFIT (FR) | 2004-01-15 | — | — | WO | claimed |
| US-20200384105-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2020-12-10 | — | — | US | disclosed |
| US-10722575-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | GENFIT (FR) | 2020-07-28 | — | — | US | disclosed |
| US-20190275146-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | GENFIT (FR) | 2019-09-12 | — | — | US | disclosed |
| US-10350181-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | GENFIT (FR) | 2019-07-16 | — | — | US | disclosed |
| EP-1525177-A1 | SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES AND PREPARATION AND USES THEREOF | Genfit (FR) | 2005-04-27 | — | — | EP | disclosed |
| EP-1519908-A2 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | Genfit (FR) | 2005-04-06 | — | — | EP | disclosed |
| WO-2005005369-A1 | PREPARATION OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES | GENFIT (FR) | 2005-01-20 | — | — | WO | disclosed |
| WO-2004005243-A2 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES | GENFIT (FR) | 2004-01-15 | — | — | WO | disclosed |
| WO-2004005233-A1 | SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES AND PREPARATION AND USES THEREOF | GENFIT (FR) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032543-A1 | Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients | PSEN1, BACE1, PSEN2 | ATG4B 3009/4885PLA2G1B 602/4885THRA 4396/4885 |
| US-20190275146-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT2, GOT1 | ATG4B 2164/4885PLA2G1B 499/4885THRA 3077/4885 |
| US-20200384105-A1 | USE OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES FOR TREATING LIVER DISORDERS | FABP1, GOT2, GOT1 | ATG4B 2164/4885PLA2G1B 499/4885THRA 3077/4885 |
| US-10722575-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | FABP1, GOT2, GOT1 | ATG4B 2164/4885PLA2G1B 499/4885THRA 3077/4885 |
| US-20120129932-A1 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | BRCA1, COL1A1, APOL1 | ATG4B 3990/4885PLA2G1B 845/4885THRA 2403/4885 |
| US-10350181-B2 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | FABP1, GOT2, GOT1 | ATG4B 2164/4885PLA2G1B 499/4885THRA 3077/4885 |
| US-20050171149-A1 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | BRCA1, LOXL1, APOL1 | ATG4B 3886/4885PLA2G1B 892/4885THRA 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.